<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-8-113</article-id><article-id pub-id-type="pmid">18433484</article-id><article-id pub-id-type="doi">10.1186/1471-2407-8-113</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (<italic>MDM2</italic>) gene</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Mittelstrass</surname><given-names>Kirstin</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>kirstin.mittelstrass@helmholtz-muenchen.de</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Sauter</surname><given-names>Wiebke</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>wiebke.sauter@helmholtz-muenchen.de</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Rosenberger</surname><given-names>Albert</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>arosenb@gwdg.de</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Illig</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>illig@helmholtz-muenchen.de</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Timofeeva</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>m.timofeeva@dkfz-heidelberg.de</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Klopp</surname><given-names>Norman</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>klopp@helmholtz-muenchen.de</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Dienemann</surname><given-names>Hendrik</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>hendrik.dienemann@thoraxklinik-heidelberg.de</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Meese</surname><given-names>Eckart</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>hgemee@med-rz.uni-sb.de</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Sybrecht</surname><given-names>Gerhard</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>prof.g.w.sybrecht@uniklinikum-saarland.de</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Woelke</surname><given-names>Gabi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>woelke@helmholtz-muenchen.de</email></contrib><contrib id="A11" contrib-type="author"><name><surname>Cebulla</surname><given-names>Mathias</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>mathias.cebulla@sanktgeorg.de</email></contrib><contrib id="A12" contrib-type="author"><name><surname>Degen</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>maria.degen@t-online.de</email></contrib><contrib id="A13" contrib-type="author"><name><surname>Morr</surname><given-names>Harald</given-names></name><xref ref-type="aff" rid="I9">9</xref><email>harald.morr.waldhof@t-online.de</email></contrib><contrib id="A14" contrib-type="author"><name><surname>Drings</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>peter.drings@thoraxklinik-heidelberg.de</email></contrib><contrib id="A15" contrib-type="author"><name><surname>Groeschel</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>inagro@med-rz.uni-sb.de</email></contrib><contrib id="A16" contrib-type="author"><name><surname>Kreymborg</surname><given-names>Karsten Grosse</given-names></name><xref ref-type="aff" rid="I10">10</xref><email>karsten.g.kreymborg@medizin.uni-leipzig.de</email></contrib><contrib id="A17" contrib-type="author"><name><surname>Haeu&#x000df;inger</surname><given-names>Karl</given-names></name><xref ref-type="aff" rid="I11">11</xref><email>gauting@asklepios.com</email></contrib><contrib id="A18" contrib-type="author"><name><surname>Hoeffken</surname><given-names>Gerd</given-names></name><xref ref-type="aff" rid="I12">12</xref><email>hoeffken@fachkrankenhasu-coswig.de</email></contrib><contrib id="A19" contrib-type="author"><name><surname>Schmidt</surname><given-names>Christine</given-names></name><xref ref-type="aff" rid="I12">12</xref><email>schmidt@fachkrnakenhaus-coswig.de</email></contrib><contrib id="A20" contrib-type="author"><name><surname>Jilge</surname><given-names>Bettina</given-names></name><xref ref-type="aff" rid="I13">13</xref><email>b.jilge@skc.de</email></contrib><contrib id="A21" contrib-type="author"><name><surname>Schmidt</surname><given-names>Wilhelm</given-names></name><xref ref-type="aff" rid="I13">13</xref><email>e.schmidt@skc.de</email></contrib><contrib id="A22" contrib-type="author"><name><surname>Ko</surname><given-names>You-Dschun</given-names></name><xref ref-type="aff" rid="I14">14</xref><email>y.ko@jk-bonn.de</email></contrib><contrib id="A23" contrib-type="author"><name><surname>Taeuscher</surname><given-names>Dagmar</given-names></name><xref ref-type="aff" rid="I15">15</xref><email>d.taeuscher@t-online.de</email></contrib><contrib id="A24" contrib-type="author"><name><surname>Chang-Claude</surname><given-names>Jenny</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>j.chang-claude@dkfz-heidelberg.de</email></contrib><contrib id="A25" contrib-type="author"><name><surname>Wichmann</surname><given-names>Heinz-Erich</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I16">16</xref><email>wichmann@helmholtz-muenchen.de</email></contrib><contrib id="A26" contrib-type="author"><name><surname>Bickeboeller</surname><given-names>Heike</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>hbickeb@gwdg.de</email></contrib><contrib id="A27" contrib-type="author"><name><surname>Risch</surname><given-names>Angela</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>a.risch@dkfz-heidelberg.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Helmholtz Center Munich, German Research Center for Environmental Health, Institute of Epidemiology, Munich/Neuherberg, Germany</aff><aff id="I2"><label>2</label>Department of Genetic Epidemiology, Georg-August University of G&#x000f6;ttingen, Medical School, G&#x000f6;ttingen, Germany</aff><aff id="I3"><label>3</label>German Cancer Research Centre (DKFZ), Heidelberg, Germany</aff><aff id="I4"><label>4</label>Thoraxklinik Heidelberg GmbH, Heidelberg, Germany</aff><aff id="I5"><label>5</label>Institute of Human Genetics, University of the Saarland, Germany</aff><aff id="I6"><label>6</label>Institute of Internal Medicine V, Medical School, University of the Saarland, Germany</aff><aff id="I7"><label>7</label>Municipal Hospital &#x0201e;Sankt Georg", Leipzig, Germany</aff><aff id="I8"><label>8</label>Clinic of Pneumology, Waldhof Elgershausen, Greifenstein, Germany</aff><aff id="I9"><label>9</label>Department Internal Medicine-Oncology, Thorax-Clinic Heidelberg GmbH, Heidelberg, Germany</aff><aff id="I10"><label>10</label>Centre for Internal Medicine, University Hospital Leipzig, Germany</aff><aff id="I11"><label>11</label>Clinic of Pneumology M&#x000fc;nchen-Gauting, Munich, Germany</aff><aff id="I12"><label>12</label>Clinic Coswig GmbH, Division Internal Medicine, Coswig, Germany</aff><aff id="I13"><label>13</label>Chemnitz Hospital, Clinic for Internal Medicine, Chemnitz, Germany</aff><aff id="I14"><label>14</label>Department of Oncology, University Hospital of Bonn, Germany</aff><aff id="I15"><label>15</label>Wald-Hospital Gera GmbH, II. Medical Clinic, Gera, Germany</aff><aff id="I16"><label>16</label>Ludwig-Maximilians-University of Munich, Institute of Medical Data Management, Biometrics and Epidemiology, Germany</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>23</day><month>4</month><year>2008</year></pub-date><volume>8</volume><fpage>113</fpage><lpage>113</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/8/113"/><history><date date-type="received"><day>19</day><month>9</month><year>2007</year></date><date date-type="accepted"><day>23</day><month>4</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Mittelstrass et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Mittelstrass et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Mittelstrass Kirstin kirstin.mittelstrass@helmholtz-muenchen.de </dc:author><dc:title> Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>BMC Cancer 8(1): 113-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2008)8:1&#x0003c;113&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>The polymorphism SNP309 (rs2279744) in the promoter region of the <italic>MDM2 </italic>gene has been shown to alter protein expression and may play a role in the susceptibility to lung cancer. The MDM2 protein is a key inhibitor of p53 and several mechanisms of MDM2/p53 interactions are presently known: modulating DNA-repair, cell-cycle control, cell growth and apoptosis.</p><p>We used 635 Caucasian patients diagnosed with lung cancer before 51 years of age and 1300 healthy gender and age frequency matched population Caucasian controls to investigate the association between the <italic>MDM2 </italic>SNP309 and the risk of developing early onset lung cancer. Conditional logistic models were applied to assess the genotype-phenotype association, adjusted for smoking.</p><p>Compared to the GG genotype, the adjusted ORs for the TG and TT genotype were 0.9 (95% CI: 0.7&#x02013;1.5) and 1.0 (95% CI: 0.7&#x02013;1.5), respectively. Also no association was found for histological subtypes of lung cancer. The strength of this study is that within young cases the genetic component to develop lung cancer may be greater. Our results indicate that the <italic>MDM2 </italic>SNP309 is not significantly associated with lung carcinogenesis but point towards gender-specific differences.</p></abstract></article-meta></front><body><sec><title>Background</title><p>Human cells have developed a complex system to protect themselves from genotoxic damage where the <italic>p53 </italic>tumor suppressor gene plays an important role in protecting against such insults by serving as an integrator of the signals produced by DNA damage. The MDM2 protein inhibits p53 transactivation activity and promotes its export from the nucleus by binding to the transcriptional activation domain of p53 [<xref ref-type="bibr" rid="B1">1</xref>] and acts as an ubiquitin ligase upon p53 pushing fast degradation of the suppressor [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>].</p><p>Recently, a SNP (SNP309, G2580T) at the intronic p53-response promoter of <italic>MDM2 </italic>was identified and associated with altered Sp1 binding affinity and expression levels of MDM2 RNA and protein [<xref ref-type="bibr" rid="B4">4</xref>]. Contradictory results were reported regarding the <italic>MDM2 </italic>SNP309 association with lung cancer [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B8">8</xref>]. In addition the polymorphism was correlated with a decreased age at the time of lung cancer diagnosis in Li-Fraumeni syndrome and sporadic sarcoma patients [<xref ref-type="bibr" rid="B4">4</xref>]. Our study is the first report on a large German case-control study of young lung cancer patients (age of onset &#x0003c; 51 years) investigating the <italic>MDM2 </italic>SNP 309.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study population</title><p>The study population consists of 635 lung cancer patients with an onset of disease &#x02264; 50 years of age and 1300 healthy population controls, all Caucasians. Controls were recruited from the KORA S3 + S4 (Cooperative Health Research in the Augsburg Region) surveys, which are large population-based consecutive cross-sectional studies [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>] and matched by gender and 3-years age groups to cases in a 1:2 matching design. In order to increase the sample size of early onset lung cancer patients we included cases from two existing studies. 472 cases were from the LUCY (<underline>LU</underline>ng <underline>C</underline>ancer in the <underline>Y</underline>oung) study. Additional 163 cases were derived from the hospital-based <underline>H</underline>eidelberg <underline>L</underline>ung <underline>C</underline>ancer (HLC) study from the Thoraxklinik Heidelberg [<xref ref-type="bibr" rid="B11">11</xref>].</p><p>The <bold>LUCY-study </bold>is a multicenter study with 31 participating clinics all over Germany. Only newly diagnosed patients with histological or cytological confirmed primary lung cancer entered the study. Detailed epidemiologic data on family history, tobacco and smoking exposure, education and occupational exposure have been collected and blood samples were taken.</p><p>The <bold>HLC-study </bold>is an ongoing hospital based case-control study. The DKFZ has recruited over 1000 LC cases at and in collaboration with the Thoraxklinik Heidelberg. 163 of these LC cases with onset of disease under age 51, recruited between 01/1997 and 12/2003 were included in the analysis. Data on occupational exposure, tobacco smoking and educational status were assessed by a self-administered questionnaire.</p><p>The <bold>KORA-study </bold>is a population based epidemiological survey of persons living in or near the city of Augsburg, Southern Germany conducted since 1984. No major population stratification between KORA (Southwest Germany) and two other cohorts from Northern Germany could be detected in an intensive study using a genomic control approach [<xref ref-type="bibr" rid="B12">12</xref>].</p><p>Informed consent was obtained from all study participants and the studies were approved by the ethical committee of the Bayerische Landes&#x000e4;rztekammer, the corresponding local ethics committees of the participating clinics and the ethical committee of the University of Heidelberg.</p></sec><sec><title>Genotyping</title><p>The detection of the <italic>MDM2 </italic>gene polymorphism (rs2279744; G &#x0003e; T; NM_002392.2) was based upon analysis of primer extension products generated from previously amplified genomic DNA using a chip-based MALDI-TOF (matrix-assisted laser desorption/ionization time-of flight) mass spectrometry platform (SEQUENOM, Inc., San Diego, CA) as described in Weidinger et al. (2004) [<xref ref-type="bibr" rid="B13">13</xref>]. Genotyping was performed by laboratory personnel blinded to case-control status. Standard genotyping quality control included 10% duplicate samples, negative and positive samples and checking for Hardy-Weinberg equilibrium (HWE).</p></sec><sec><title>Statistical analysis</title><p>Hardy Weinberg Equilibrium (HWE) was tested using a log-likelihood test. Conditional logistic regression models were applied to test for a genotype-phenotype association and gene-smoking interaction, with conditioning on the matched variables age groups (&#x02264; 40 years, 41&#x02013;45 years, 46&#x02013;50 years) and gender. The amount of smoking exposure (s. table <xref ref-type="table" rid="T1">1</xref> for definition) was considered as a covariate to adjust for a smoking-related increase in lung cancer risk. The overall level of significance was set to 5%. We investigated differences between multiple characteristics (age of onset, gender, LC subtype and <italic>MDM2 </italic>SNP390 genotype) of both cases-samples by calculating a propensity score, which is defined as the conditional probability of assignment to a particular case-sample given a vector of observed covariates [<xref ref-type="bibr" rid="B14">14</xref>]. We then calculated kappa as measurement of agreement between true and the assigned membership to a case-sample and performed a McNemar's test for agreement between these.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Characteristics of lung cancer cases and healthy controls</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Category</bold></td><td align="right"><bold>Group</bold></td><td align="center" colspan="2"><bold>Cases (n = 635)</bold></td><td align="center"><bold>Controls</bold></td></tr><tr><td></td><td></td><td colspan="3"><hr></hr></td></tr><tr><td></td><td></td><td align="center"><bold>LUCY-study</bold><break/><bold>(n = 472)</bold></td><td align="center"><bold>HLC-study</bold><break/><bold>(n = 163)</bold></td><td align="center"><bold>KORA-study</bold><break/><bold>(n = 1300)</bold></td></tr></thead><tbody><tr><td align="left">gender</td><td align="right">men</td><td align="center">66% (310)</td><td align="center">59% (96)</td><td align="center">63% (819)</td></tr><tr><td></td><td align="right">women</td><td align="center">34% (162)</td><td align="center">41% (67)</td><td align="center">37% (481)</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">age at diagnosis (mean &#x000b1; SD)</td><td align="right">men</td><td align="center">45.4 &#x000b1; 4.1</td><td align="center">45.4 &#x000b1; 3.7</td><td align="center">45.2 &#x000b1; 4.3</td></tr><tr><td></td><td align="right">women</td><td align="center">44.5 &#x000b1; 4.6</td><td align="center">45.1 &#x000b1; 4.6</td><td align="center">44.7 &#x000b1; 4.7</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">age at diagnosis (men)</td><td align="right">&#x02264; 40 years</td><td align="center">13% (40)</td><td align="center">11% (11)</td><td align="center">14% (116)</td></tr><tr><td></td><td align="right">41&#x02013;45 years</td><td align="center">32% (99)</td><td align="center">33% (32)</td><td align="center">31% (251)</td></tr><tr><td></td><td align="right">46&#x02013;50 years</td><td align="center">55% (171)</td><td align="center">55% (53)</td><td align="center">55% (451)</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">age at diagnosis (women)</td><td align="right">&#x02264; 40 years</td><td align="center">17% (28)</td><td align="center">16% (11)</td><td align="center">17% (83)</td></tr><tr><td></td><td align="right">41&#x02013;45 years</td><td align="center">31% (51)</td><td align="center">25% (17)</td><td align="center">30% (144)</td></tr><tr><td></td><td align="right">46&#x02013;50 years</td><td align="center">51% (83)</td><td align="center">58% (39)</td><td align="center">53% (255)</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">LC subtypes (men)</td><td align="right">NSCLC-Adenocarcinoma</td><td align="center">26% (81)</td><td align="center">35% (34)</td><td></td></tr><tr><td></td><td align="right">other NSCLC</td><td align="center">40% (125)</td><td align="center">43% (41)</td><td></td></tr><tr><td></td><td align="right">SCLC</td><td align="center">26% (81)</td><td align="center">20% (19)</td><td></td></tr><tr><td></td><td align="right">other types</td><td align="center">7% (22)</td><td align="center">2% (2)</td><td></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">LC subtypes (women)</td><td align="right">NSCLC-Adenocarcinoma</td><td align="center">44% (71)</td><td align="center">54% (36)</td><td></td></tr><tr><td></td><td align="right">other NSCLC</td><td align="center">22% (36)</td><td align="center">24% (16)</td><td></td></tr><tr><td></td><td align="right">SCLC</td><td align="center">25% (41)</td><td align="center">16% (11)</td><td></td></tr><tr><td></td><td align="right">other types</td><td align="center">9% (14)</td><td align="center">6% (4)</td><td></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">smoking exposure (packyears)</td><td align="right">minimally exposed (0&#x02013;10)</td><td align="center">12% (57)</td><td align="center">13% (21)</td><td align="center">54% (712)</td></tr><tr><td></td><td align="right">lightly exposed (11&#x02013;20)</td><td align="center">17% (81)</td><td align="center">8% (13)</td><td align="center">14% (178)</td></tr><tr><td></td><td align="right">moderately exposed (21&#x02013;30)</td><td align="center">31% (144)</td><td align="center">20% (33)</td><td align="center">15% (188)</td></tr><tr><td></td><td align="right">highly exposed (31++)</td><td align="center">39% (186)</td><td align="center">52% (85)</td><td align="center">15% (192)</td></tr><tr><td></td><td align="right">unknown</td><td align="center">0.9% (4)</td><td align="center">7% (11)</td><td align="center">2% (30)</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><italic>MDM2 </italic>SNP309 genotypes*</td><td align="right">TT</td><td align="center">42% (199)</td><td align="center">44% (71)</td><td align="center">42% (547)</td></tr><tr><td></td><td align="right">TG</td><td align="center">47% (222)</td><td align="center">44% (71)</td><td align="center">46% (598)</td></tr><tr><td></td><td align="right">GG</td><td align="center">10% (49)</td><td align="center">13% (21)</td><td align="center">12% (149)</td></tr><tr><td></td><td align="right">unknown</td><td align="center">0.3% (2)</td><td align="center">--</td><td align="center">0.5% (6)</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">mean age at diagnosis (95% CI)</td><td align="right">TT</td><td align="center">45.1 (44.5&#x02013;45.7)</td><td align="center">44.8 (43.7&#x02013;45.8)</td><td></td></tr><tr><td></td><td align="right">TG</td><td align="center">45.3 (44.7&#x02013;45.8)</td><td align="center">45.6 (44.7&#x02013;46.5)</td><td></td></tr><tr><td></td><td align="right">GG</td><td align="center">44.6 (43.3&#x02013;45.9)</td><td align="center">45.9 (44.2&#x02013;47.6)</td><td></td></tr></tbody></table><table-wrap-foot><p>LUCY-study: Lung Cancer in the Young study; HLC-Study: Heidelberg lung cancer study; Other NSCLC = other non small cell lung cancers (NSCLC excluding adenocarcinoma), SCLC = small cell lung cancer, other types = other kinds of lung cancer</p></table-wrap-foot></table-wrap><p>All analyses were performed with SAS 9.1<sup>&#x000ae;</sup>. Power analyses for the single marker association was done according to the method of Slager 2001 [<xref ref-type="bibr" rid="B15">15</xref>] and for the single marker interaction tests it was accomplished by using Nquery Advisor 4.0.</p></sec></sec><sec><title>Results</title><sec><title>Population characteristics</title><p>There was no statistically significant difference in the distribution of gender (p = 0.13) and age (p = 0.80) between patients and controls. The distribution of the histology subtypes within the cases can be seen in table <xref ref-type="table" rid="T1">1</xref>. Although one might see a higher percentage of NSCLC-Adenocarcinoma within HCL-cases, the difference between both case-populations was by far not significant (p = 0.617). In total, there are no major differences between both case-populations. Applying the propensity score approach we found no agreement between the true and the assigned membership to a case-sample (kappa 0.01; 95% CI: -0.1 to 0.1). Thus we have no evidence to assume group differences shown by the multiple characteristics considered (p = 1.00).</p></sec><sec><title>Genotyping</title><p>The genotyping success rates were above 99.5%. No discordance between the duplicates was found.</p></sec><sec><title>Associations of the MDM2 SNP309 with lung cancer</title><p>No deviations from HWE were found in the genotype distribution of the <italic>MDM2 </italic>polymorphism among controls (p = 0.453) or cases (p = 0.474). All but eight samples were successfully genotyped for the <italic>MDM2 </italic>SNP309. The minor allele frequency (MAF) was 0.34 (CI: 0.35&#x02013;0.33). Lung cancer was not found to be associated with the <italic>MDM2 </italic>SNP309 (p = 0.988). Compared to the GG genotype, the smoking adjusted ORs for the TG and TT genotypes were 1.0 (95% CI: 0.7&#x02013;1.5) and 1.0 (95% CI: 0.7&#x02013;1.5), respectively. Both case populations compared separately to the controls showed no significant associations (Table <xref ref-type="table" rid="T2">2</xref>). Gender related subgroup analysis yielded no association of the <italic>MDM2 </italic>SNP309 and lung cancer (Table <xref ref-type="table" rid="T2">2</xref>, <xref ref-type="table" rid="T3">3</xref>, <xref ref-type="table" rid="T4">4</xref>). Also no influence in lung cancer risk by the <italic>MDM2 </italic>SNP309 was observed for the diverse histological subtypes of lung cancer (Table <xref ref-type="table" rid="T3">3</xref>, <xref ref-type="table" rid="T4">4</xref>, <xref ref-type="table" rid="T5">5</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Association of <italic>MDM2 </italic>SNP309 with lung cancer within both case-populations</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>genotype</bold></td><td align="center"><bold>OR</bold></td><td align="center"><bold>95% CI</bold></td><td align="center"><bold>p-value</bold></td></tr></thead><tbody><tr><td align="left" colspan="4"><bold>LUCY </bold>cases (n = 470) vs. KORA controls (n = 815)</td></tr><tr><td align="center">TG vs. GG</td><td align="center">1.1<sup>&#x000a7;</sup></td><td align="center">0.7&#x02013;1.6</td><td align="center">0.794</td></tr><tr><td align="center">TT vs. GG</td><td align="center">1.0<sup>&#x000a7;</sup></td><td align="center">0.7&#x02013;1.6</td><td align="center">0.841</td></tr><tr><td align="left" colspan="4"><bold>men</bold>: LUCY cases (n = 309) vs. KORA controls (n = 815)</td></tr><tr><td align="center">TG vs. GG</td><td align="center">1.1<sup>&#x000a7;&#x000a7;</sup></td><td align="center">0.7&#x02013;1.8</td><td align="center">0.706</td></tr><tr><td align="center">TT vs. GG</td><td align="center">1.1<sup>&#x000a7;&#x000a7;</sup></td><td align="center">0.7&#x02013;1.8</td><td align="center">0.751</td></tr><tr><td align="left" colspan="4"><bold>women</bold>: LUCY cases (n = 161) vs. KORA controls (n = 815)</td></tr><tr><td align="center">TG vs. GG</td><td align="center">1.0<sup>&#x000a7;&#x000a7;</sup></td><td align="center">0.5&#x02013;2.1</td><td align="center">0.937</td></tr><tr><td align="center">TT vs. GG</td><td align="center">1.0<sup>&#x000a7;&#x000a7;</sup></td><td align="center">0.5&#x02013;2.1</td><td align="center">0.966</td></tr><tr><td align="left" colspan="3">gender difference in genotypic ORs</td><td align="center">0.778</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left" colspan="4"><bold>HLC </bold>cases (n = 163) vs. KORA controls (n = 479)</td></tr><tr><td align="center">TG vs. GG</td><td align="center">0.9<sup>&#x000a7;</sup></td><td align="center">0.5&#x02013;1.7</td><td align="center">0.761</td></tr><tr><td align="center">TT vs. GG</td><td align="center">1.0<sup>&#x000a7;</sup></td><td align="center">0.5&#x02013;1.7</td><td align="center">0.906</td></tr><tr><td align="left" colspan="4"><bold>men</bold>: HLC cases (n = 96) vs. KORA controls (n = 479)</td></tr><tr><td align="center">TG vs. GG</td><td align="center">1.2<sup>&#x000a7;&#x000a7;</sup></td><td align="center">0.5&#x02013;3.0</td><td align="center">0.648</td></tr><tr><td align="center">TT vs. GG</td><td align="center">1.6<sup>&#x000a7;&#x000a7;</sup></td><td align="center">0.7&#x02013;3.7</td><td align="center">0.314</td></tr><tr><td align="left" colspan="4"><bold>women</bold>: HLC cases (n = 67) vs. KORA controls (n = 479)</td></tr><tr><td align="center">TG vs. GG</td><td align="center">0.7<sup>&#x000a7;&#x000a7;</sup></td><td align="center">0.3&#x02013;1.6</td><td align="center">0.372</td></tr><tr><td align="center">TT vs. GG</td><td align="center">0.5<sup>&#x000a7;&#x000a7;</sup></td><td align="center">0.2&#x02013;1.3</td><td align="center">0.159</td></tr><tr><td align="left" colspan="3">gender difference in genotypic ORs</td><td align="center">0.083</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left" colspan="4"><bold>HLC </bold>cases vs. <bold>LUCY </bold>cases (distribution of TT/TG/GG)</td></tr><tr><td align="center">all</td><td></td><td></td><td align="center"><sup>$</sup>0.773</td></tr><tr><td align="center">men</td><td></td><td></td><td align="center"><sup>$</sup>0.383</td></tr><tr><td align="center">women</td><td></td><td></td><td align="center"><sup>$</sup>0.100</td></tr></tbody></table><table-wrap-foot><p><sup>&#x000a7; </sup>conditional to age/gender-strata (6 groups) and adjusted for smoking exposure<sup>&#x000a7;&#x000a7; </sup>conditional to age-strata (3 groups) and adjusted for smoking exposure and gender<sup>$</sup>. Fishers Exact Test</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Association of <italic>MDM2 </italic>SNP309 with lung cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>gender</bold></td><td align="center"><bold>Genotype</bold></td><td align="center"><bold>OR</bold></td><td align="center"><bold>95% CI</bold></td><td align="center"><bold>p-value</bold></td></tr></thead><tbody><tr><td align="left">men*</td><td align="center">TG vs. GG</td><td align="center">1.1</td><td align="center">0.7 &#x02013; 2.0</td><td align="center">0.630</td></tr><tr><td align="left">men*</td><td align="center">TT vs. GG</td><td align="center">1.2</td><td align="center">0.7 &#x02013; 2.2</td><td align="center">0.504</td></tr><tr><td align="left">women*</td><td align="center">TG vs. GG</td><td align="center">0.9</td><td align="center">0.5 &#x02013; 1.6</td><td align="center">0.723</td></tr><tr><td align="left">women*</td><td align="center">TT vs. GG</td><td align="center">0.8</td><td align="center">0.5 &#x02013; 1.3</td><td align="center">0.565</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>histology</bold></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">NSCLC-Adenocarcinoma**</td><td align="center">TG vs. GG</td><td align="center">1.0</td><td align="center">0.6 &#x02013; 1.7</td><td align="center">0.991</td></tr><tr><td align="left">NSCLC-Adenocarcinoma**</td><td align="center">TT vs. GG</td><td align="center">1.0</td><td align="center">0.6 &#x02013; 1.8</td><td align="center">0.890</td></tr><tr><td align="left">other NSCLC**</td><td align="center">TG vs. GG</td><td align="center">1.0</td><td align="center">0.6 &#x02013; 1.8</td><td align="center">0.873</td></tr><tr><td align="left">other NSCLC**</td><td align="center">TT vs. GG</td><td align="center">0.9</td><td align="center">0.5 &#x02013; 1.6</td><td align="center">0.751</td></tr><tr><td align="left">SCLC**</td><td align="center">TG vs. GG</td><td align="center">1.0</td><td align="center">0.5 &#x02013; 1.9</td><td align="center">0.980</td></tr><tr><td align="left">SCLC**</td><td align="center">TT vs. GG</td><td align="center">1.2</td><td align="center">0.6 &#x02013; 2.1</td><td align="center">0.637</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>smoking exposure (packyears)</bold></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">lightly exposed (11&#x02013;20 PY)***</td><td align="center">TT vs. GG</td><td align="center">1.0</td><td align="center">0.6 &#x02013; 1.8</td><td align="center">0.928</td></tr><tr><td align="left">lightly exposed (11&#x02013;20 PY)***</td><td align="center">TG vs. GG</td><td align="center">1.0</td><td align="center">0.5 &#x02013; 1.7</td><td align="center">0.857</td></tr><tr><td align="left">moderately exposed (21&#x02013;30 PY)***</td><td align="center">TT vs. GG</td><td align="center">1.0</td><td align="center">0.6 &#x02013; 1.7</td><td align="center">0.960</td></tr><tr><td align="left">moderately exposed (21&#x02013;30 PY)***</td><td align="center">TG vs. GG</td><td align="center">0.9</td><td align="center">0.6 &#x02013; 1.6</td><td align="center">0.822</td></tr><tr><td align="left">highly exposed (31++ PY)***</td><td align="center">TT vs. GG</td><td align="center">0.9</td><td align="center">0.5 &#x02013; 1.4</td><td align="center">0.595</td></tr><tr><td align="left">highly exposed (31++ PY)***</td><td align="center">TG vs. GG</td><td align="center">0.8</td><td align="center">0.5 &#x02013; 1.3</td><td align="center">0.369</td></tr></tbody></table><table-wrap-foot><p>*conditional to age-strata (3 groups: &#x02264; 40 years, 41&#x02013;45 years, 46&#x02013;50 years), adjusted for smoking exposure; **conditional to age/gender-strata (6 groups) and adjusted for smoking exposure; ***conditional to age/gender-strata (6 groups)</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Association of <italic>MDM2 </italic>SNP309 with lung cancer within NSCLC cases</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>genotype</bold></td><td align="center"><bold>OR</bold></td><td align="center"><bold>95% CI</bold></td><td align="center"><bold>p-value</bold></td></tr></thead><tbody><tr><td align="left" colspan="4"><bold>all</bold>: NSCLC cases (n = 434) vs. controls (n = 1295)</td></tr><tr><td align="center">TG vs. GG</td><td align="center">1.1<sup>&#x000a7;</sup></td><td align="center">0.7&#x02013;1.6</td><td align="center">0.828</td></tr><tr><td align="center">TT vs. GG</td><td align="center">1.0<sup>&#x000a7;</sup></td><td align="center">0.7&#x02013;1.5</td><td align="center">0.841</td></tr><tr><td align="left" colspan="4"><bold>men</bold>: NSCLC cases (n = 280) vs. controls (n = 815)</td></tr><tr><td align="center">TG vs. GG</td><td align="center">1.2<sup>&#x000a7;&#x000a7;</sup></td><td align="center">0.7&#x02013;2.9</td><td align="center">0.422</td></tr><tr><td align="center">TT vs. GG</td><td align="center">1.2<sup>&#x000a7;&#x000a7;</sup></td><td align="center">0.7&#x02013;2.9</td><td align="center">0.515</td></tr><tr><td align="left" colspan="4"><bold>women</bold>: NSCLC cases (n = 154) vs. controls (n = 479)</td></tr><tr><td align="center">TG vs. GG</td><td align="center">0.8<sup>&#x000a7;&#x000a7;</sup></td><td align="center">0.4&#x02013;1.6</td><td align="center">0.471</td></tr><tr><td align="center">TT vs. GG</td><td align="center">0.7<sup>&#x000a7;&#x000a7;</sup></td><td align="center">0.4&#x02013;4.0</td><td align="center">0.323</td></tr><tr><td align="left" colspan="3">gender difference in genotypic ORs</td><td align="center">0.237</td></tr></tbody></table><table-wrap-foot><p><sup>&#x000a7; </sup>conditional to age/gender-strata (6 groups) and adjusted for smoking exposure<sup>&#x000a7;&#x000a7; </sup>conditional to age-strata (3 groups) and adjusted for smoking exposure and gender</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T5"><label>Table 5</label><caption><p><italic>MDM2 </italic>SNP309 genotypes</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold><italic>Group</italic></bold></td><td align="right" colspan="2"><bold><italic>MDM2 SNP309 genotypes</italic></bold></td><td align="center" colspan="2"><bold>Cases (n = 635)</bold></td><td align="center"><bold><italic>Controls</italic></bold></td></tr><tr><td></td><td></td><td></td><td colspan="3"><hr></hr></td></tr><tr><td></td><td></td><td></td><td align="center"><bold>LUCY-study</bold><break/><bold>(n = 472)</bold></td><td align="center"><bold>HLC-study</bold><break/><bold>(n = 163)</bold></td><td align="center"><bold>KORA-study</bold><break/><bold>(n = 1300)</bold></td></tr></thead><tbody><tr><td align="left">gender</td><td align="right">men</td><td align="right">TT</td><td align="center">128 (41%)</td><td align="center">47 (49%)</td><td align="center">350 (43%)</td></tr><tr><td></td><td></td><td align="right">TG</td><td align="center">148 (48%)</td><td align="center">42 (44%)</td><td align="center">366 (45%)</td></tr><tr><td></td><td></td><td align="right">GG</td><td align="center">33 (11%)</td><td align="center">7 (7%)</td><td align="center">99 (12%)</td></tr><tr><td></td><td></td><td align="right">unknown</td><td align="center">1 (0%)</td><td></td><td align="center">3 (0%)</td></tr><tr><td></td><td align="right">women</td><td align="right">TT</td><td align="center">71 (44%)</td><td align="center">24 (36%)</td><td align="center">197 (41%)</td></tr><tr><td></td><td></td><td align="right">TG</td><td align="center">74 (46%)</td><td align="center">29 (43%)</td><td align="center">232 (48%)</td></tr><tr><td></td><td></td><td align="right">GG</td><td align="center">16 (10%)</td><td align="center">14 (21%)</td><td align="center">50 (10%)</td></tr><tr><td></td><td></td><td align="right">unknown</td><td align="center">1 (0%)</td><td></td><td align="center">3 (0%)</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">age at diagnosis</td><td align="right">&#x02264; 40 years</td><td align="right">TT</td><td align="center">30 (44%)</td><td align="center">11 (50%)</td><td align="center">85 (43%)</td></tr><tr><td></td><td></td><td align="right">TG</td><td align="center">30 (44%)</td><td align="center">8 (36%)</td><td align="center">91 (46%)</td></tr><tr><td></td><td></td><td align="right">GG</td><td align="center">6 (9%)</td><td align="center">3 (14%)</td><td align="center">21 (11%)</td></tr><tr><td></td><td></td><td align="right">unknown</td><td align="center">2 (3%)</td><td></td><td align="center">2 (1%)</td></tr><tr><td></td><td align="right">41&#x02013;45 years</td><td align="right">TT</td><td align="center">58 (39%)</td><td align="center">21 (43%)</td><td align="center">172 (44%)</td></tr><tr><td></td><td></td><td align="right">TG</td><td align="center">73 (49%)</td><td align="center">23 (47%)</td><td align="center">185 (47%)</td></tr><tr><td></td><td></td><td align="right">GG</td><td align="center">19 (13%)</td><td align="center">5 (10%)</td><td align="center">37 (9%)</td></tr><tr><td></td><td></td><td align="right">unknown</td><td></td><td></td><td align="center">1 (0%)</td></tr><tr><td></td><td align="right">46&#x02013;50 years</td><td align="right">TT</td><td align="center">111 (44%)</td><td align="center">39 (42%)</td><td align="center">290 (41%)</td></tr><tr><td></td><td></td><td align="right">TG</td><td align="center">119 (47%)</td><td align="center">40 (43%)</td><td align="center">322 (46%)</td></tr><tr><td></td><td></td><td align="right">GG</td><td align="center">24 (9%)</td><td align="center">13 (14%)</td><td align="center">91 (13%)</td></tr><tr><td></td><td></td><td align="right">unknown</td><td></td><td></td><td align="center">3 (0%)</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">smoking exposure level (SEL)</td><td align="right">minimally exposed</td><td align="right">TT</td><td align="center">28 (49%)</td><td align="center">7 (33%)</td><td align="center">297 (42%)</td></tr><tr><td></td><td align="right">(0&#x02013;10 PY)</td><td align="right">TG</td><td align="center">19 (33%)</td><td align="center">12 (57%)</td><td align="center">332 (47%)</td></tr><tr><td></td><td></td><td align="right">GG</td><td align="center">9 (16%)</td><td align="center">2 (10%)</td><td align="center">81 (11%)</td></tr><tr><td></td><td></td><td align="right">unknown</td><td align="center">1 (2%)</td><td></td><td align="center">2 (0%)</td></tr><tr><td></td><td align="right">lightly exposed (&#x0003e; 10&#x02013;20 PY)</td><td align="right">TT</td><td align="center">29 (36%)</td><td align="center">7 (54%)</td><td align="center">72 (40%)</td></tr><tr><td></td><td></td><td align="right">TG</td><td align="center">42 (52%)</td><td align="center">5 (38%)</td><td align="center">81 (46%)</td></tr><tr><td></td><td></td><td align="right">GG</td><td align="center">9 (11%)</td><td align="center">1 (8%)</td><td align="center">24 (13%)</td></tr><tr><td></td><td></td><td align="right">unknown</td><td align="center">1 (1%)</td><td></td><td align="center">1 (1%)</td></tr><tr><td></td><td align="right">moderately exposed (&#x0003e; 20&#x02013;30 PY)</td><td align="right">TT</td><td align="center">65 (45%)</td><td align="center">13 (39%)</td><td align="center">81 (44%)</td></tr><tr><td></td><td></td><td align="right">TG</td><td align="center">70 (49%)</td><td align="center">15 (45%)</td><td align="center">86 (46%)</td></tr><tr><td></td><td></td><td align="right">GG</td><td align="center">9 (6%)</td><td align="center">5 (15%)</td><td align="center">19 (10%)</td></tr><tr><td></td><td></td><td align="right">unknown</td><td></td><td></td><td></td></tr><tr><td></td><td align="right">highly exposed</td><td align="right">TT</td><td align="center">76 (41%)</td><td align="center">41 (48%)</td><td align="center">84 (44%)</td></tr><tr><td></td><td align="right">(&#x0003e; 30++ PY)</td><td align="right">TG</td><td align="center">89 (48%)</td><td align="center">33 (39%)</td><td align="center">87 (45%)</td></tr><tr><td></td><td></td><td align="right">GG</td><td align="center">21 (11%)</td><td align="center">11 (13%)</td><td align="center">21 (11%)</td></tr><tr><td></td><td></td><td align="right">unknown</td><td></td><td></td><td></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">LC subtypes</td><td align="right">NSCLC- Adenocarcinoma</td><td align="right">TT</td><td align="center">63 (41%)</td><td align="center">35 (50%)</td><td></td></tr><tr><td></td><td></td><td align="right">TG</td><td align="center">75 (49%)</td><td align="center">23 (33%)</td><td></td></tr><tr><td></td><td></td><td align="right">GG</td><td align="center">13 (9%)</td><td align="center">12 (17%)</td><td></td></tr><tr><td></td><td></td><td align="right">unknown</td><td align="center">1 (1%)</td><td></td><td></td></tr><tr><td></td><td align="right">other NSCLC</td><td align="right">TT</td><td align="center">68 (43%)</td><td align="center">17 (30%)</td><td></td></tr><tr><td></td><td></td><td align="right">TG</td><td align="center">73 (46%)</td><td align="center">34 (60%)</td><td></td></tr><tr><td></td><td></td><td align="right">GG</td><td align="center">19 (12%)</td><td align="center">6 (11%)</td><td></td></tr><tr><td></td><td align="right">SCLC</td><td align="right">TT</td><td align="center">55 (45%)</td><td align="center">15 (50%)</td><td></td></tr><tr><td></td><td></td><td align="right">TG</td><td align="center">55 (45%)</td><td align="center">12 (40%)</td><td></td></tr><tr><td></td><td></td><td align="right">GG</td><td align="center">13 (11%)</td><td align="center">3 (10%)</td><td></td></tr><tr><td></td><td align="right">other types</td><td align="right">TT</td><td align="center">13 (27%)</td><td align="center">4 (40%)</td><td></td></tr><tr><td></td><td></td><td align="right">TG</td><td align="center">19 (39%)</td><td align="center">2 (20%)</td><td></td></tr><tr><td></td><td></td><td align="right">GG</td><td align="center">4 (8%)</td><td></td><td></td></tr><tr><td></td><td></td><td align="right">unknown</td><td align="center">13 (27%)</td><td align="center">4 (40%)</td><td></td></tr></tbody></table></table-wrap><p>Furthermore it was investigated whether an interaction existed between the MDM2 SNP309 and the smoking status. We did not find an association between the MDM2 SNP309 and lung cancer for any of the defined smoking exposure level groups (Table <xref ref-type="table" rid="T3">3</xref>, <xref ref-type="table" rid="T5">5</xref>).</p><p>Even though no significant difference between both case-populations could be stated statistically, we observed twice as many female GG-carriers among HLC-cases (21%) than in the control- or LUCY population (10%) (Table <xref ref-type="table" rid="T5">5</xref>). We also observed an enrichment of NSCLC- and NSCLC adenocarcinoma-cases in the HLC-sample (78%) compared to the LUCY-sample (66%). Lind et al. (2006) [<xref ref-type="bibr" rid="B6">6</xref>] recently reported a gender specific risk disposing effect of the T-allele of <italic>MDM2 </italic>SNP309 for NSCLC cases. We therefore additionally performed a subgroup analysis restricted to NSCLC-cases and tested for gender differences. Compared to the GG genotype, the smoking adjusted ORs for the TG and TT genotypes for female NSCLC-cases were 0.8 (95% CI: 0.4&#x02013;1.6) and 0.71 (95% CI: 0.4&#x02013;4.0), respectively. For men the ORs were 1.2 (95% CI: 0.7&#x02013;2.8) and 1.2 (95% CI: 0.7&#x02013;2.9), respectively (Table <xref ref-type="table" rid="T4">4</xref>). Although a possible NSCLC risk modification of <italic>MDM2 SNP309 </italic>seems to be reverse between men and women, we failed to achieve significance for this gender difference (p = 0.237). We also tested a gender specific genetic association within both case-samples separately. Neither within all HLC-cases (p = 0.083) nor within all LUCY-cases (p = 0.778) were significant gender differences found (Table <xref ref-type="table" rid="T2">2</xref>).</p><p><italic>MDM2 </italic>SNP309 was recently reported to be associated with an earlier onset of disease [<xref ref-type="bibr" rid="B4">4</xref>]. The average age at the time of diagnosis in our cases overall was not significantly different (p = 0.923) between the variant genotypes (Table <xref ref-type="table" rid="T1">1</xref>) and can be assumed as homogeneous between both case-samples (p = 0.7157). The mean age of diagnosis of men was 45.2 (median = 46.0 years, range 26.0 &#x02013; 50.0 years) and of women 44.7 years (median = 46.0 years, range 24.0 &#x02013; 50.0 years). Women, however, with the <italic>MDM2 </italic>SNP309 were diagnosed at a younger age (8 months) compared to males, but this was not statistically significant (p = 0.059, 95% CI: 0 to 16 months). Within the LUCY-case population this gender difference was 10 months (95% CI: 0.3 to 20 months, p = 0.044), and only 6 months (95% CI: -10 to 22 months, p = 0.496) in the much smaller HLC-case population.</p></sec></sec><sec><title>Discussion</title><p>Reports have shown an increased risk of lung cancer for the G allele of the <italic>MDM2 </italic>SNP309 in Korean and Chinese populations [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. In contrast, in our study of 635 Caucasian lung cancer patients with age of onset &#x0003c; 51 years and 1300 controls the <italic>MDM2 </italic>SNP309 was not associated with lung cancer. We did not observe a significant overall association either with the G allele or with the T allele as reported by Li et al. (2006) where they showed an increased lung cancer risk with the T/T genotype in a non-Hispanic white population [<xref ref-type="bibr" rid="B18">18</xref>]. We had a 90% power (alpha = 0.05, two sided test) to detect a minimum overall OR of 1.4 for the <italic>MDM2 </italic>SNP309 T allele. Thus our study had sufficient power to detect an OR of 1.6 (95% CI: 1.1&#x02013;2.5) and 1.8 (95% CI: 1.5&#x02013;2.3) reported in other studies [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. The estimated allele frequency (T: 0.66, G: 0.34) agrees well with further reported allele frequencies in Caucasian populations [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. Differences between the two case populations were statistically not palpable (Table <xref ref-type="table" rid="T1">1</xref>, <xref ref-type="table" rid="T2">2</xref>, <xref ref-type="table" rid="T3">3</xref>, <xref ref-type="table" rid="T4">4</xref>, <xref ref-type="table" rid="T5">5</xref>) but the HLC-sample was enriched with NSCLC-cases. According to Steffens et al. 2006 [<xref ref-type="bibr" rid="B12">12</xref>] we can assume the German population to be nearly free of population stratification, which may lead to false positive or false negative association findings in genetic case control studies. Differences in ethnicity between our population and those reported by Zhang et al. 2006 [<xref ref-type="bibr" rid="B7">7</xref>], Park et al. 2006 [<xref ref-type="bibr" rid="B16">16</xref>] and Jun et al. 2007 [<xref ref-type="bibr" rid="B19">19</xref>] may provide a partial explanation for the lack of association in our study. On the other hand Hu et al. 2006 [<xref ref-type="bibr" rid="B5">5</xref>] also did not observe an association between the <italic>MDM2 </italic>SNP309 and lung cancer in a Chinese population. Our results were similar to the report of Pine et al. (2006) [<xref ref-type="bibr" rid="B8">8</xref>]. They also did not find any overall association between the <italic>MDM2 </italic>SNP309 and lung cancer in a Caucasian (USA) population. Similarly, we did not observe an interaction between the <italic>MDM2 </italic>SNP309 and smoking. A combined analysis of the available genotype data of the <italic>MDM2 </italic>SNP309 showed an increased risk of lung cancer for the GG versus the TT genotype (OR: 1.3, 95% CI: 1.1&#x02013;1.4) [<xref ref-type="bibr" rid="B20">20</xref>]. A main difference between the two study populations is the age of cases. Therefore one possible explanation would be, that the <italic>MDM2 </italic>variant is only associated with risk of later onset lung cancer. On the other hand a large study of 1787 Caucasian lung cancer patients could also not confirm the results of this meta-analysis. They did not find any significant association of the <italic>MDM2 </italic>SNP309 and lung cancer [<xref ref-type="bibr" rid="B21">21</xref>]. The populations used in the meta-analysis are mostly of Asian origin so possibly pointing to population heterogeneity.</p><p>Lind et al. (2006) [<xref ref-type="bibr" rid="B6">6</xref>] recently reported a gender specific risk disposing effect of the T allele of <italic>MDM2 </italic>SNP309 for NSCLC cases. They investigated NSCLC-cases and found female carriers of the GG-genotype associated to LC by an OR of 4.1, while male homozygotes showed a non significant OR of 1.3. Our data slightly tends to confirm this finding, but the corresponding OR for NSCLC women is just 1.4 (1/0.71 of Table <xref ref-type="table" rid="T4">4</xref>), which is much smaller and not significant (p = 0.323). In our study none of the gender specific ORs nor a test of gender differences yielded significance. But we noticed discrepancies of such a gender specific genetic association between the two case-samples of our investigation. A gender difference was almost significant (p = 0.08) for the much smaller single center case-sample of the HLC-study. There, the OR for female carriers of the GG-Genotype (corresponding to Lind et al. (2006)) was 1.9 (1/0.54 of Table <xref ref-type="table" rid="T4">4</xref>) and for male carriers 0.6 (1/1.56 of Table <xref ref-type="table" rid="T4">4</xref>). With n = 67 female and n = 96 male cases these subsamples are quite small and the tests for association are underpowered. Thus our investigation provides no significance for such gender specific associations by itself. Comparing our study samples to that of Lind et al. (2006) the major difference is the age of onset of LC. The presented investigation focused on early onset LC cases which are in the mean 20 years younger than those of Lind et al. (2006). As the population by Lind et al. (2006) is of Norwegian origin there might also be different gene-environmental interactions.</p><p><italic>MDM2 </italic>SNP309 was reported by Bond et al. 2004 [<xref ref-type="bibr" rid="B4">4</xref>] to be associated with an earlier onset of disease for Li-Fraumeni syndrome and sporadic sarcoma patients. We did not observe a lower age of diagnosis in our study, similar findings are also described by Hu et al. 2006 [<xref ref-type="bibr" rid="B5">5</xref>] and Pine et al. 2006 [<xref ref-type="bibr" rid="B8">8</xref>]. Our sample size is large enough to detect a shift of two years for the time of diagnosis with 90% power (alpha = 0.05) for heterozygous as well as for homozygous allele carriers. Recently Bond et al. 2006 [<xref ref-type="bibr" rid="B22">22</xref>] reviewed the possible interaction between the SNP309 and the oestrogen receptor status in women. Within women of the LUCY case population we could observe an earlier onset of disease of 10 months (95% CI: 0.3 to 20 months, p = 0.044), but only 6 months (95% CI: -10 to 22 months, p = 0.496) in the by far smaller HLC-case population. Recent data suggest that the promoter polymorphism in the <italic>MDM2 </italic>gene may influence the age of cancer onset in a gender specific way [<xref ref-type="bibr" rid="B23">23</xref>-<xref ref-type="bibr" rid="B25">25</xref>].</p></sec><sec><title>Conclusion</title><p>Given that lung cancer is a result of gene-environmental interaction, the genetic component may be a particularly strong risk factor among early onset lung cancer patients. In our sample, after controlling for gender and other characteristics, the overall data suggest that the <italic>MDM2 </italic>SNP309 might not be a sufficient risk factor of lung carcinogenesis not even in young cases where the genetic component might have a larger contribution to the risk of disease. It might modify the time of tumour onset, especially in women, supporting the model, that female-specific hormones, such as oestrogen, could allow the SNP309 to accelerate tumour formation. Our investigation provides no significance for gender specific associations by itself; it points only towards gender specific differences. Therefore further studies have to be conducted to explicitly study these gender-specific effects.</p></sec><sec><title>Abbreviations</title><p>CI: confidence interval; HLCS: Heidelberg lung cancer study; KORA: Cooperative Health Research in the Augsburg Region; LC: lung cancer; LUCY: lung cancer in the young; MALDI-TOF: matrix-assisted laser desorption/ionization time-of flight; NSCLC: none small cell lung cancer; OR: odds ratio; PY: packyear; SCLC: small cell lung cancer.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>KM carried out the molecular genetic study and drafted the manuscript. WS, NK carried out the molecular genetic study. AR, JCC performed the statistical analysis. HEW, HB, ARi, TI conceived the study, and participated in its design and coordination. GW proband recruitment and data acquisitions. MT data acquisitions. NK, HD, EM, GS, MC, MD, HM, PD, AG, KG, KH, GH, CS, BJ, WS, YK, DT recruited the lung cancer cases in different hospitals. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/8/113/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The computational assistance of G. Fischer, H. Grallert and C. Gieger, Institute of Epidemiology, GSF-National Research Center for Environment and Health, Neuherberg, Germany is gratefully acknowledged. We thank Rolf Holle, C. Hanrieder and A. Steinwachs, Institute of Epidemiology, GSF-National Research Center for Environment and Health, Neuherberg, Germany for their assistance in data management. We also thank all individuals who participated as cases or controls in this study and the KORA Study Center and their co-workers for organizing and conducting the data collection. The authors wish to thank all patients, their physicians and nurses involved in sample and data collection in the following hospitals: Dr. Heidi Kleen &#x02013; Aurich, Lungenklinik Heckeshorn &#x02013; Berlin, Berufsgenossenschaftliche Kliniken Bochum, Medizinische Poliklinik der Universit&#x000e4;t Bonn, Pneumologische Klinik des Zentralkrankenhaus Bremen Ost, Bereich Innere Medizin des Fachkrankenhaus Coswig GmbH, Fachklinik f&#x000fc;r Atemwegserkrankungen &#x02013; Donaustauf, Abt. Pneumologie &#x02013; Ruhrlandklinik Essen, II. Medizinische Klinik des Wald-Klinikum Gera, Pneumologische Klinik &#x02013; Greifenstein, Zentrum f&#x000fc;r Pneumologie und Thoraxchirurgie des Krankenhaus Gro&#x000df;hansdorf, Klinik f&#x000fc;r Pneumologie am Klinikum Hannover Heidehaus, Abt. Innere Medizin-Onkologie der Thoraxklinik &#x02013; Heidelberg, Innere Medizin V des Universit&#x000e4;tsklinik des Saarlandes &#x02013; Homburg, Fachklinik f&#x000fc;r Lungenerkrankungen &#x02013; Immenhausen, Innere Medizin des Klinikum Chemnitz &#x02013; Krankenhaus K&#x000fc;chwald, Abt. Pneumologie der Universit&#x000e4;tsklinik Leipzig, Robert-Koch-Klinik des St&#x000e4;dtischen Klinikums St. Georg &#x02013; Leipzig, Abt. Pneumologie des Klinikum der LMU-M&#x000fc;nchen, Pneumologische Klinik, M&#x000fc;nchen-Gauting, Lungenklinik Unterstedt des Diakoniekrankenhaus Rotenburg. We are also grateful to the LUCY-Consortium and the KORA Study Group (Head: H.E. Wichmann).</p><p>This work was funded in part by the National Genome Research Network (NGFN), the DFG (BI 576/2-1; BI 576/2&#x02013;2), the Helmholzgemeinschaft (HGF) and the Federal office for Radiation Protection (Bfs: STSch4454). Genotyping was performed in the Genome Analysis Center (GAC) of the GSF Research Center for Environment and Health. The KORA Surveys were financed by the GSF, which is funded by the German Federal Ministry of Education, Science, Research and Technology and the State of Bavaria. Recruitment of the cases in Heidelberg was in part financed by the Deutsche Krebshilfe.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Momand</surname><given-names>J</given-names></name><name><surname>Zambetti</surname><given-names>GP</given-names></name></person-group><article-title>Mdm-2: "big brother" of p53</article-title><source>J Cell Biochem</source><year>1997</year><volume>64</volume><fpage>343</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">9057092</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-4644(19970301)64:3&#x0003c;343::AID-JCB1&#x0003e;3.0.CO;2-V</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname><given-names>DA</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Levine</surname><given-names>AJ</given-names></name></person-group><article-title>Functions of the MDM2 oncoprotein</article-title><source>Cell Mol Life Sci</source><year>1999</year><volume>55</volume><fpage>96</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">10065155</pub-id><pub-id pub-id-type="doi">10.1007/s000180050273</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kubbutat</surname><given-names>MH</given-names></name><name><surname>Jones</surname><given-names>SN</given-names></name><name><surname>Vousden</surname><given-names>KH</given-names></name></person-group><article-title>Regulation of p53 stability by Mdm2</article-title><source>Nature</source><year>1997</year><volume>387</volume><fpage>299</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">9153396</pub-id><pub-id pub-id-type="doi">10.1038/387299a0</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bond</surname><given-names>GL</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Bond</surname><given-names>EE</given-names></name><name><surname>Robins</surname><given-names>H</given-names></name><name><surname>Lutzker</surname><given-names>SG</given-names></name><name><surname>Arva</surname><given-names>NC</given-names></name><name><surname>Bargonetti</surname><given-names>J</given-names></name><name><surname>Bartel</surname><given-names>F</given-names></name><name><surname>Taubert</surname><given-names>H</given-names></name><name><surname>Wuerl</surname><given-names>P</given-names></name><name><surname>Onel</surname><given-names>K</given-names></name><name><surname>Yip</surname><given-names>L</given-names></name><name><surname>Hwang</surname><given-names>SJ</given-names></name><name><surname>Strong</surname><given-names>LC</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name><name><surname>Levine</surname><given-names>AJ</given-names></name></person-group><article-title>A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans</article-title><source>Cell</source><year>2004</year><volume>119</volume><fpage>591</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">15550242</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2004.11.022</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name></person-group><article-title>Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population</article-title><source>Int J Cancer</source><year>2006</year><volume>118</volume><fpage>1275</fpage><lpage>1278</lpage><pub-id pub-id-type="pmid">16152608</pub-id><pub-id pub-id-type="doi">10.1002/ijc.21463</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lind</surname><given-names>H</given-names></name><name><surname>Zienolddiny</surname><given-names>S</given-names></name><name><surname>Ekstrom</surname><given-names>PO</given-names></name><name><surname>Skaug</surname><given-names>V</given-names></name><name><surname>Haugen</surname><given-names>A</given-names></name></person-group><article-title>Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer</article-title><source>Int J Cancer</source><year>2006</year><volume>119</volume><fpage>718</fpage><lpage>721</lpage><pub-id pub-id-type="pmid">16496380</pub-id><pub-id pub-id-type="doi">10.1002/ijc.21872</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Miao</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>D</given-names></name></person-group><article-title>Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer</article-title><source>Hum Mutat</source><year>2006</year><volume>27</volume><fpage>110</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">16287156</pub-id><pub-id pub-id-type="doi">10.1002/humu.20277</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pine</surname><given-names>SR</given-names></name><name><surname>Mechanic</surname><given-names>LE</given-names></name><name><surname>Bowman</surname><given-names>ED</given-names></name><name><surname>Welsh</surname><given-names>JA</given-names></name><name><surname>Chanock</surname><given-names>SC</given-names></name><name><surname>Shields</surname><given-names>PG</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name></person-group><article-title>MDM2 SNP309 and SNP354 are not associated with lung cancer risk</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2006</year><volume>15</volume><fpage>1559</fpage><lpage>1561</lpage><pub-id pub-id-type="pmid">16896050</pub-id><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-06-0217</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holle</surname><given-names>R</given-names></name><name><surname>Happich</surname><given-names>M</given-names></name><name><surname>Lowel</surname><given-names>H</given-names></name><name><surname>Wichmann</surname><given-names>HE</given-names></name></person-group><article-title>KORA--a research platform for population based health research</article-title><source>Gesundheitswesen</source><year>2005</year><volume>67 </volume><fpage>S19</fpage><lpage>S25</lpage><pub-id pub-id-type="pmid">16032513</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wichmann</surname><given-names>HE</given-names></name><name><surname>Gieger</surname><given-names>C</given-names></name><name><surname>Illig</surname><given-names>T</given-names></name></person-group><article-title>KORA-gen--resource for population genetics, controls and a broad spectrum of disease phenotypes</article-title><source>Gesundheitswesen</source><year>2005</year><volume>67 Suppl 1</volume><fpage>S26</fpage><lpage>S30</lpage><pub-id pub-id-type="pmid">16032514</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dally</surname><given-names>H</given-names></name><name><surname>Edler</surname><given-names>L</given-names></name><name><surname>Jager</surname><given-names>B</given-names></name><name><surname>Schmezer</surname><given-names>P</given-names></name><name><surname>Spiegelhalder</surname><given-names>B</given-names></name><name><surname>Dienemann</surname><given-names>H</given-names></name><name><surname>Drings</surname><given-names>P</given-names></name><name><surname>Schulz</surname><given-names>V</given-names></name><name><surname>Kayser</surname><given-names>K</given-names></name><name><surname>Bartsch</surname><given-names>H</given-names></name><name><surname>Risch</surname><given-names>A</given-names></name></person-group><article-title>The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose</article-title><source>Pharmacogenetics</source><year>2003</year><volume>13</volume><fpage>607</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">14515059</pub-id><pub-id pub-id-type="doi">10.1097/00008571-200310000-00004</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steffens</surname><given-names>M</given-names></name><name><surname>Lamina</surname><given-names>C</given-names></name><name><surname>Illig</surname><given-names>T</given-names></name><name><surname>Bettecken</surname><given-names>T</given-names></name><name><surname>Vogler</surname><given-names>R</given-names></name><name><surname>Entz</surname><given-names>P</given-names></name><name><surname>Suk</surname><given-names>EK</given-names></name><name><surname>Toliat</surname><given-names>MR</given-names></name><name><surname>Klopp</surname><given-names>N</given-names></name><name><surname>Caliebe</surname><given-names>A</given-names></name><name><surname>Konig</surname><given-names>IR</given-names></name><name><surname>Kohler</surname><given-names>K</given-names></name><name><surname>Ludemann</surname><given-names>J</given-names></name><name><surname>Lacava</surname><given-names>AD</given-names></name><name><surname>Fimmers</surname><given-names>R</given-names></name><name><surname>Lichtner</surname><given-names>P</given-names></name><name><surname>Ziegler</surname><given-names>A</given-names></name><name><surname>Wolf</surname><given-names>A</given-names></name><name><surname>Krawczak</surname><given-names>M</given-names></name><name><surname>Nurnberg</surname><given-names>P</given-names></name><name><surname>Hampe</surname><given-names>J</given-names></name><name><surname>Schreiber</surname><given-names>S</given-names></name><name><surname>Meitinger</surname><given-names>T</given-names></name><name><surname>Wichmann</surname><given-names>HE</given-names></name><name><surname>Roeder</surname><given-names>K</given-names></name><name><surname>Wienker</surname><given-names>TF</given-names></name><name><surname>Baur</surname><given-names>MP</given-names></name></person-group><article-title>SNP-based analysis of genetic substructure in the German population</article-title><source>Hum Hered</source><year>2006</year><volume>62</volume><fpage>20</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">17003564</pub-id><pub-id pub-id-type="doi">10.1159/000095850</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weidinger</surname><given-names>S</given-names></name><name><surname>Klopp</surname><given-names>N</given-names></name><name><surname>Wagenpfeil</surname><given-names>S</given-names></name><name><surname>Rummler</surname><given-names>L</given-names></name><name><surname>Schedel</surname><given-names>M</given-names></name><name><surname>Kabesch</surname><given-names>M</given-names></name><name><surname>Schafer</surname><given-names>T</given-names></name><name><surname>Darsow</surname><given-names>U</given-names></name><name><surname>Jakob</surname><given-names>T</given-names></name><name><surname>Behrendt</surname><given-names>H</given-names></name><name><surname>Wichmann</surname><given-names>HE</given-names></name><name><surname>Ring</surname><given-names>J</given-names></name><name><surname>Illig</surname><given-names>T</given-names></name></person-group><article-title>Association of a STAT 6 haplotype with elevated serum IgE levels in a population based cohort of white adults</article-title><source>J Med Genet</source><year>2004</year><volume>41</volume><fpage>658</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">15342695</pub-id><pub-id pub-id-type="doi">10.1136/jmg.2004.020263</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenbaum</surname><given-names>PR</given-names></name><name><surname>Donald</surname><given-names>BR</given-names></name></person-group><article-title>The Central Role of the Propensity Score in Observational Studies for Causal Effects</article-title><source>Biometrika</source><year>1983</year><volume>70</volume><fpage>41</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1093/biomet/70.1.41</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slager</surname><given-names>SL</given-names></name><name><surname>Schaid</surname><given-names>DJ</given-names></name></person-group><article-title>Case-control studies of genetic markers: power and sample size approximations for Armitage's test for trend</article-title><source>Hum Hered</source><year>2001</year><volume>52</volume><fpage>149</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">11588398</pub-id><pub-id pub-id-type="doi">10.1159/000053370</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Choi</surname><given-names>JE</given-names></name><name><surname>Kim</surname><given-names>EJ</given-names></name><name><surname>Jang</surname><given-names>JS</given-names></name><name><surname>Han</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>WK</given-names></name><name><surname>Kang</surname><given-names>YM</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name></person-group><article-title>MDM2 309T&#x0003e;G polymorphism and risk of lung cancer in a Korean population</article-title><source>Lung Cancer</source><year>2006</year><volume>54</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">16876289</pub-id><pub-id pub-id-type="doi">10.1016/j.lungcan.2006.06.008</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jun</surname><given-names>HJ</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>WK</given-names></name><name><surname>Choi</surname><given-names>JE</given-names></name><name><surname>Jang</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>EJ</given-names></name><name><surname>Cha</surname><given-names>SI</given-names></name><name><surname>Kim</surname><given-names>DS</given-names></name><name><surname>Kam</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>CH</given-names></name><name><surname>Kang</surname><given-names>YM</given-names></name><name><surname>Jung</surname><given-names>TH</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name></person-group><article-title>Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer</article-title><source>Mol Carcinog</source><year>2007</year><volume>46</volume><fpage>100</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">17013834</pub-id><pub-id pub-id-type="doi">10.1002/mc.20279</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Zhai</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Chamberlain</surname><given-names>RM</given-names></name><name><surname>Spitz</surname><given-names>MR</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name></person-group><article-title>MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis</article-title><source>Carcinogenesis</source><year>2006</year><volume>27</volume><fpage>2028</fpage><lpage>2033</lpage><pub-id pub-id-type="pmid">16675470</pub-id><pub-id pub-id-type="doi">10.1093/carcin/bgl047</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jun</surname><given-names>HJ</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>WK</given-names></name><name><surname>Choi</surname><given-names>JE</given-names></name><name><surname>Jang</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>EJ</given-names></name><name><surname>Cha</surname><given-names>SI</given-names></name><name><surname>Kim</surname><given-names>DS</given-names></name><name><surname>Kam</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>CH</given-names></name><name><surname>Kang</surname><given-names>YM</given-names></name><name><surname>Jung</surname><given-names>TH</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name></person-group><article-title>Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer</article-title><source>Mol Carcinog</source><year>2006</year><pub-id pub-id-type="pmid">16649250</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilkening</surname><given-names>S</given-names></name><name><surname>Bermejo</surname><given-names>JL</given-names></name><name><surname>Hemminki</surname><given-names>K</given-names></name></person-group><article-title>MDM2 SNP309 and cancer risk: a combined analysis</article-title><source>Carcinogenesis</source><year>2007</year><volume>28</volume><fpage>2262</fpage><lpage>2267</lpage><pub-id pub-id-type="pmid">17827408</pub-id><pub-id pub-id-type="doi">10.1093/carcin/bgm191</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Wheatley-Price</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Heist</surname><given-names>RS</given-names></name><name><surname>Asomaning</surname><given-names>K</given-names></name><name><surname>Wain</surname><given-names>JC</given-names></name><name><surname>Lynch</surname><given-names>TJ</given-names></name><name><surname>Su</surname><given-names>L</given-names></name><name><surname>Christiani</surname><given-names>DC</given-names></name></person-group><article-title>Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk</article-title><source>Int J Cancer</source><year>2008</year><volume>122</volume><fpage>915</fpage><lpage>918</lpage><pub-id pub-id-type="pmid">17957785</pub-id><pub-id pub-id-type="doi">10.1002/ijc.23178</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bond</surname><given-names>GL</given-names></name><name><surname>Hirshfield</surname><given-names>KM</given-names></name><name><surname>Kirchhoff</surname><given-names>T</given-names></name><name><surname>Alexe</surname><given-names>G</given-names></name><name><surname>Bond</surname><given-names>EE</given-names></name><name><surname>Robins</surname><given-names>H</given-names></name><name><surname>Bartel</surname><given-names>F</given-names></name><name><surname>Taubert</surname><given-names>H</given-names></name><name><surname>Wuerl</surname><given-names>P</given-names></name><name><surname>Hait</surname><given-names>W</given-names></name><name><surname>Toppmeyer</surname><given-names>D</given-names></name><name><surname>Offit</surname><given-names>K</given-names></name><name><surname>Levine</surname><given-names>AJ</given-names></name></person-group><article-title>MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>5104</fpage><lpage>5110</lpage><pub-id pub-id-type="pmid">16707433</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-0180</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bond</surname><given-names>GL</given-names></name><name><surname>Menin</surname><given-names>C</given-names></name><name><surname>Bertorelle</surname><given-names>R</given-names></name><name><surname>Alhopuro</surname><given-names>P</given-names></name><name><surname>Aaltonen</surname><given-names>LA</given-names></name><name><surname>Levine</surname><given-names>AJ</given-names></name></person-group><article-title>MDM2 SNP309 accelerates colorectal tumour formation in women</article-title><source>J Med Genet</source><year>2006</year><volume>43</volume><fpage>950</fpage><lpage>952</lpage><pub-id pub-id-type="pmid">16825430</pub-id><pub-id pub-id-type="doi">10.1136/jmg.2006.043539</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galic</surname><given-names>V</given-names></name><name><surname>Willner</surname><given-names>J</given-names></name><name><surname>Wollan</surname><given-names>M</given-names></name><name><surname>Garg</surname><given-names>R</given-names></name><name><surname>Garcia</surname><given-names>R</given-names></name><name><surname>Goff</surname><given-names>BA</given-names></name><name><surname>Gray</surname><given-names>HJ</given-names></name><name><surname>Swisher</surname><given-names>EM</given-names></name></person-group><article-title>Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas</article-title><source>Genes Chromosomes Cancer</source><year>2007</year><volume>46</volume><fpage>239</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">17171684</pub-id><pub-id pub-id-type="doi">10.1002/gcc.20407</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>H</given-names></name><name><surname>Hinoda</surname><given-names>Y</given-names></name><name><surname>Kikuno</surname><given-names>N</given-names></name><name><surname>Kawamoto</surname><given-names>K</given-names></name><name><surname>Suehiro</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Dahiya</surname><given-names>R</given-names></name></person-group><article-title>MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>4123</fpage><lpage>4129</lpage><pub-id pub-id-type="pmid">17634539</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-0609</pub-id></citation></ref></ref-list></back></article> 